Exploring New Strategies in Adult Ph+ ALL

Exploring New Strategies in Adult Ph+ ALL

Not a member of My prIME? Join now for instant access.

Meeting Overview

Discover new options for the treatment of adult Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL) at prIME Oncology’s official satellite symposium at the annual hematology meeting in Atlanta, Georgia. Attendees will have the opportunity to engage with expert faculty speakers on topics, including the use of non-intensive versus aggressive initial therapy, how deep sequencing can influence treatment decisions, and the role for transplantation in the treatment of Ph+ ALL.

Friday satellite symposium on Exploring New Strategies in Adult Ph+ ALL preceding the 59th ASH Annual Meeting & Exposition

Date and Location

Friday, December 8, 2017
12.30 PM – 3.30 PM

Centennial I
Hyatt Regency Atlanta
265 Peachtree Street NE
Atlanta, Georgia 30303



Friday, December 8, 2017
12.30 PM – 3.30 PM



Atlanta, Georgia, United States



2.5 AMA PRA Category 1 Credits

Friday, December 8, 2017

12.30 PM Registration and lunch
1.00 PM Welcome and introduction
Hagop Kantarjian, MD
1.05 PM Making it personal from the start: Initial assessment in adult Ph+ ALL
Hagop Kantarjian, MD
1.25 PM Q & A
1.30 PM Is less best? Examining non-intensive initial therapy in Ph+ ALL
Giovanni Martinelli, MD, PhD
1.50 PM Q & A
1.55 PM Hit me with your best shot: The case for aggressive initial therapy in Ph+ ALL
Elias Jabbour, MD
2.15 PM Q & A
2.20 PM Is transplantation still needed in Ph+ ALL?
Sergio Giralt, MD
2.40 PM Q & A
2.45 PM How low can we go? The rationale for deep sequencing in preventing relapses in Ph+ ALL
Hugues de Lavallade, MD, PhD
3.05 PM Q & A
3.10 PM Faculty panel discussion/audience participation
Entire faculty panel
3.25 PM What have we learned?
Hagop Kantarjian, MD
3.30 PM prIME Points™
Hagop Kantarjian, MD


  • Hagop M. Kantarjian, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Faculty

  • Sergio Giralt, MD, FACPMemorial Sloan Kettering Cancer Center
    New York, New York, United States
  • Elias Jabbour, MDThe University of Texas
    MD Anderson Cancer Center
    Houston, Texas, United States
  • Hugues de Lavallade, MD, PhDKing’s College Hospital
    NHS Foundation Trust
    London, United Kingdom
  • Giovanni Martinelli, MD, PhDUniversity of Bologna
    Bologna, Italy

Target Audience

This educational activity is specifically designed to meet the needs of hematologists, medical oncologists, and other healthcare professionals involved in the treatment of patients with ALL.

Learning Objectives

After successful completion of this educational activity, participants should be able to:

  • Identify risk factors for relapse in Ph+ ALL, including cytogenetic abnormalities and failure to achieve complete molecular remission
  • Interpret findings from contemporary techniques like qRT-PCR and deep sequencing to better predict outcomes and adjust therapy for patients with Ph+ ALL
  • Select an appropriate therapeutic approach for Ph+ ALL, taking into consideration patient fitness, diagnostic findings, and factors related to hematopoietic stem cell transplantation


This educational activity is supported by a grant from Takeda Oncology.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

prIME Oncology designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


This activity is provided by prIME Oncology.


prIME Oncology complies with all Sunshine Act reporting requirements as outlined by CMS and applicable manufacturers and with EFPIA Disclosure Code reporting requirements.


Disclosure of Relevant Financial Relationships

prIME Oncology assesses the relevant financial relationships of its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.